The revenue of a pharma manufacturer is not necessarily an indicator of quality. Many international pharma firms of supposed good repute have repeatedly been found to be committing egregious levels of good manufacturing practice (GMP) violations, and even when they have production lines that stand up to FDA audits, parallel production lines in the same firm that aren't subject to FDA scrutiny (as they produce for non-US markets) often are churning out very suspicious products for local / developing world consumption. And even US-based production lines can be churning out product with potential defect for quite some time during gaps between FDA audits - it happens all the time.
A really eye opening read on the global pharma quality situation: https://www.nytimes.com/2019/05/13/books/review/bottle-of-li...